These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 35989085)

  • 81. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
    Duraiswamy J; Freeman GJ; Coukos G
    Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.
    Fujiwara K; Shigematsu K; Tachibana M; Okada N
    IUBMB Life; 2020 Aug; 72(8):1649-1658. PubMed ID: 32255257
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Intratumoral immunotherapy: using the tumor as the remedy.
    Marabelle A; Tselikas L; de Baere T; Houot R
    Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
    Kopalli SR; Kang TB; Lee KH; Koppula S
    Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.
    Flies DB; Sandler BJ; Sznol M; Chen L
    Yale J Biol Med; 2011 Dec; 84(4):409-21. PubMed ID: 22180678
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway.
    Zheng S; Zhang K; Zhang X; Xiao Y; Wang T; Jiang S
    J Med Chem; 2022 Sep; 65(18):11900-11912. PubMed ID: 36083840
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
    Xia Y; Medeiros LJ; Young KH
    Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.
    O'Neill RE; Cao X
    Adv Cancer Res; 2019; 143():145-194. PubMed ID: 31202358
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 91. B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects.
    Yu L; Wang Y; Shao S; Yang M; Niu H; Yu Q; Wang X
    Tumori; 2015; 101(5):549-54. PubMed ID: 26045125
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies.
    Adams R; Osborn G; Mukhia B; Laddach R; Willsmore Z; Chenoweth A; Geh JLC; MacKenzie Ross AD; Healy C; Barber L; Tsoka S; Sanz-Moreno V; Lacy KE; Karagiannis SN
    Oncoimmunology; 2022; 11(1):2127284. PubMed ID: 36211808
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Not Available].
    Mignard X; Chaabane N; Fallet V; Wislez M
    Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
    Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
    Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
    Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
    Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Immune checkpoint blockade therapy for bladder cancer treatment.
    Kim J
    Investig Clin Urol; 2016 Jun; 57 Suppl 1(Suppl 1):S98-S105. PubMed ID: 27326412
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.
    Yi M; Jiao D; Qin S; Chu Q; Wu K; Li A
    Mol Cancer; 2019 Mar; 18(1):60. PubMed ID: 30925919
    [TBL] [Abstract][Full Text] [Related]  

  • 98. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Checkpoint inhibitor immunotherapy in kidney cancer.
    Xu W; Atkins MB; McDermott DF
    Nat Rev Urol; 2020 Mar; 17(3):137-150. PubMed ID: 32020040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.